今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

华语电影盛宴再添新篇章！第四届新时代国际电影节将在澳门隆重举行

澳门 - 由多家中国香港和澳门主流媒体联合发起和主办的第四届新时代国际电影节金扬花奖将于12月20日在澳门永利皇宫隆重举行。本届电影节以“礼赞新时代奋进新征程”为宗旨，旨在弘扬“中国梦”精神，推动华语电影产业发展，促进文化交流合作。

汇聚业界精英 共襄电影盛举

新时代国际电影节自创办以来，一直致力于表彰优秀电影作品，扶持电影人才，推动华语电影产业发展。本届电影节将继续秉承这一宗旨，邀请国内外知名电影人担任评委，对过去一年多来在华语影坛涌现出的优秀电影作品进行评选。

奖项设置多元 彰显电影魅力

本届新时代国际电影节金扬花奖设置了最佳影片、最佳导演、最佳男主角、最佳女主角、最佳编剧等多个奖项，涵盖了电影创作的各个方面，将从不同角度展现华语电影的魅力。

澳门举办 别具意义

本届电影节选择在澳门举办，具有重要的现实意义。澳门作为连接中国内地和港澳台的重要桥梁，一直以来都是文化交流合作的重要平台。将电影节举办地选址澳门，有利于促进华语电影与世界各国电影的交流合作，推动中华优秀传统文化的传播。

展望未来 期待辉煌

第四届新时代国际电影节的举办，必将为华语电影产业发展注入新的活力，为广大观众带来更多优质的电影作品。让我们共同期待这场华语电影盛宴，共同见证华语电影的辉煌成就。

以下为第四届新时代国际电影节金扬花奖的相关信息：

• 举办时间：2023年12月20日
• 举办地点：澳门永利皇宫
• 主办方：多家中国香港和澳门主流媒体
• 奖项设置：最佳影片、最佳导演、最佳男主角、最佳女主角、最佳编剧等多个奖项